Slate Path Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Slate Path Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-213,000	Closed	-$31M	–	31
2020 Q3	$31M	Sell	213,000 -371,000	-64%	-$52.7M	1.76%	16
2020 Q2	$86.5M	Sell	584,000 -134,000	-19%	-$18.1M	5.1%	11
2020 Q1	$78.2M	Sell	718,000 -97,000	-12%	-$11.2M	5.99%	6
2019 Q4	$93.9M	Buy	815,000 +200,000	+33%	+$19.9M	5.06%	9
2019 Q3	$49.5M	Hold	615,000	–	–	3.27%	11
2019 Q2	$44.6M	Buy	615,000 +135,000	+28%	+$10.4M	2%	12
2019 Q1	$44.9M	Hold	480,000	–	–	3.63%	10
2018 Q4	$35M	Hold	480,000	–	–	3.94%	11
2018 Q3	$42M	Hold	480,000	–	–	5.64%	9
2018 Q2	$47.3M	Buy	480,000 +105,000	+28%	+$10.4M	3.57%	11
2018 Q1	$44.7M	Sell	375,000 -72,000	-16%	-$9.28M	2.85%	13
2017 Q4	$56.8M	Sell	447,000 -114,000	-20%	-$14.3M	5.59%	7
2017 Q3	$65.9M	Sell	561,000 -574,000	-51%	-$49M	3.47%	12
2017 Q2	$90.5M	Sell	1,135,000 -865,000	-43%	-$55.3M	3.44%	11
2017 Q1	$103M	Hold	2,000,000	–	–	5.02%	11
2016 Q4	$74.9M	Buy	2,000,000 +775,000	+63%	+$32.4M	2.28%	12
2016 Q3	$83M	Buy	1,225,000 +90,000	+8%	+$6.35M	1.38%	7
2016 Q2	$63M	Hold	1,135,000	–	–	4.93%	10
2016 Q1	$71.2M	Buy	1,135,000 +410,000	+57%	+$27.3M	5.53%	8
2015 Q4	$68.3M	Buy	725,000 +130,000	+22%	+$12.1M	7.38%	7
2015 Q3	$47.8M	Sell	595,000 -86,759	-13%	-$9.64M	5.48%	7
2015 Q2	$81.7M	Sell	681,759 -173,241	-20%	-$20.7M	8.93%	8
2015 Q1	$89.3M	Hold	855,000	–	–	5.63%	9
2014 Q4	$82.9M	Hold	855,000	–	–	5.8%	9
2014 Q3	$66.8M	Buy	855,000 +257,000	+43%	+$16.6M	3%	12
2014 Q2	$37.8M	Buy	598,000 +186,460	+45%	+$11.1M	1.06%	16
2014 Q1	$27.6M	Sell	411,540 -588,460	-59%	-$45.6M	2.09%	13
2013 Q4	$64.3M	Sell	1,000,000 -260,000	-21%	-$15.5M	2.22%	15
2013 Q3	$80.7M	Buy	1,260,000 +210,000	+20%	+$10.5M	4.2%	13
2013 Q2	$32.5M	Buy	+1,050,000	New	+$27.9M	1.76%	13

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Slate Path Capital's ALNY Position: Q4 2020 in Review

Slate Path Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 213,000 shares — an estimated $31M sold.

Slate Path Capital first reported a position in ALNY in Q2 2013 and held it in 30 quarters. The position peaked at $103M in Q1 2017. 374 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

Slate Path Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Slate Path Capital sold 213,000 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $31M.
Slate Path Capital first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 30 quarters.
Slate Path Capital's Alnylam Pharmaceuticals position peaked at $103M in Q1 2017.
374 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Slate Path Capital's 13F filing for Q4 2020, filed 16 Feb 2021.